Press release: Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons. bioarctic.se/en/lecanemab-d…

PRESS RELEASE: Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer’s disease to the U.S. FDA completed. bioarctic.se/en/submission-…

PRESS RELEASE: BioArctic’s focus on Sustainable Innovation qualifies company for new ESG Responsibility Index at Nasdaq Stockholm. bioarctic.se/en/bioarctics-…

Press release: The Nomination Committee’s proposal for the election of Board members and Chairperson of the Board in BioArctic AB. bioarctic.se/en/the-nominat…

Press release: BioArctic publishes the Annual Report for 2023 bioarctic.se/en/bioarctic-p…

Press release: BioArctic and Eisai sign research evaluation agreement regarding a potential new treatment combining BioArctic’s proprietary BrainTransporter™ technology with an undisclosed Alzheimer drug candidat. bioarctic.se/en/bioarctic-a…

We’re pleased to share an update on the subcutaneous (SC) development program of our treatment for early #AlzheimersDisease (AD).

PRESS RELEASE: Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing. bioarctic.com/en/eisai-initi…

PRESS RELEASE: Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 – March 2025) bioarctic.com/en/eisai-proje…

PRESS RELEASE: Interim Report for the period January – March 2024 bioarctic.com/en/interim-rep…

PRESS RELEASE: Leqembi[®] approved for the treatment of Alzheimer’s disease in South Korea bioarctic.com/en/leqembi-app…

PRESS RELEASE: FDA accepts filing of Leqembi[®] (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer’s Disease. bioarctic.com/en/fda-accepts…

Press release: Leqembi[®] (lecanemab) launched in China bioarctic.com/en/leqembi-lec…

PRESS RELEASE: Leqembi approved for the treatment of Alzheimer’s disease in Hong Kong bioarctic.com/en/leqembi-app…

PRESS RELEASE: Leqembi approved for the treatment of Alzheimer’s disease in Israel bioarctic.com/en/leqembi-app…

PRESS RELEASE: Long-term treatment data for lecanemab to be presented at AAIC 2024 bioarctic.com/en/long-term-t…

PRESS RELEASE: Leqembi revenue more than doubled – totaled JPY 6.3 billion in the second quarter 2024. bioarctic.com/en/leqembi-rev…

PRESS RELEASE: Leqembi approved for the treatment of Alzheimer’s disease in the United Arab Emirates. bioarctic.com/en/leqembi-app…

PRESS RELEASE: Leqembi (lecanemab) authorized for early Alzheimer’s disease in Great Britain. bioarctic.com/en/leqembi-lec…

PRESS RELEASE: Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology. bioarctic.com/en/study-resul…